HLX02 manufacturers

Henlius is a global biopharmaceutical company focused on developing and commercializing high-quality biologics, including biosimilars and innovative monoclonal antibodies. The company's lead product, HLX02 (trastuzumab biosimilar), is marketed as Zercepac in Europe and Hanquyou in China, representing the first Chinese biosimilar to receive approval in both regions. Henlius maintains a diversified pipeline targeting oncology, autoimmune, and ophthalmic diseases, supported by an integrated platform covering R&D, manufacturing, and commercialization. With state-of-the-art GMP-certified facilities in Shanghai, the company has established a strong international presence through strategic partnerships with global pharmaceutical leaders. Henlius is committed to improving patient access to advanced therapies through cost-effective innovation and large-scale production capabilities.